Canterbury Regional Cancer and Blood Service (Haematology) / Page 1 of 3
UKALL 14
Induction Phase 1 / Height / cm
Weight / kg
BSA / m2
Cycle length: / 28 days / CBC / Day 1 / Limits / Hypersensitivities/Allergies
Antiemetics
Domperidone 10 mg PO QID
± Cyclizine 50mg PO/IV TDS / Agent
Daunorubicin
Vincristine
Peg-Asparaginase
DOSE MODIFIED:Yes / No / Round
5mg
0.2mg
75units (IU)
Date
Destination: / BMTU / Hb
Neuts
Plts
Reference: UKALL 14 trial protocol –v5.0 – 20/07/12
Day / Date / Time / Agent / Dose / Route / Instructions / Doctor / Nurse / Check / Start / Stop
-7 to -1
(Steroid pre-phase) / Dexamethasone 6mg/m2/day / mg / PO / Prescribe on regular medication chart (pre-phase for 5-7 days)
Days 1-4, 8-11, 15-18 / Dexamethasone 10 mg/m2
(max 20 mg) / mg / PO / Prescribe once daily in the morning on regular medication chart
Continuous from day 1 / Imatinib
(Philadelphia +ve patients only) / mg / PO / Patients with Philadelphia positive disease should also receive continuous daily Imatinib, PO, starting at 400mg, aiming to escalate to 600mg within 2 weeks, if tolerated. This should be continued until transplant wherever possible. Prescribe on regular medication chart.
1 / Ondansetron / 8 / mg / PO/IV / Give one hour prior to chemotherapy
Daunorubicin30mg/m2 / mg / IV / In 100 mL sodium chloride 0.9 % over 20 minutes (via side arm of fast running sodium chloride 0.9 % if peripheral)
*Sodium chloride 0.9 % / 250 / mL / IV
Vincristine 1.4mg/m2 (max 2mg) / mg / IV / In 50mLsodium chloride 0.9 % free run over 10 minutes
Ondansetron / 8 / mg / PO/IV
  • * Sodium chloride 0.9 % not required for central line administration of daunorubicin
  • Daunorubicin should be infused through a CVAD. Free flow (DO NOT PUMP) if given peripherally
  • Azole antifungals should not be given within 72 hours of vincristine (i.e. not in this cycle)

Consultant: Special authority:

NZMC Reg. No: Peg-Asparaginase

UKALL 14
Induction Phase 1 / Height / cm
Weight / kg
BSA / m2
Day / Date / Time / Agent / Dose / Route / Instructions / Doctor / Nurse / Check / Start / Stop
4 / # Peg-Asparaginase 1000 units/m2
(Philadelphia –ve patients ≤ 40 years only) / units / IV / In 100mLsodium chloride 0.9 % over at least 1 hour
8 / Ondansetron / 8 / mg / PO/IV / Give one hour prior to chemotherapy
Daunorubicin30mg/m2 / mg / IV / In 100 mL sodium chloride 0.9 % over 20 minutes (via side arm of fast running sodium chloride 0.9 % if peripheral)
*Sodium chloride 0.9 % / 250 / mL / IV
Vincristine 1.4mg/m2 (max 2mg) / IV / In 50 mLsodium chloride 0.9 % free run over 10 minutes
Ondansetron / 8 / mg / PO/IV
14 / Methotrexate 12 mg / IT / See separate intrathecal chemotherapy medication chart (C160016)
15 / Ondansetron / 8 / mg / PO/IV / Give one hour prior to chemotherapy
Daunorubicin30mg/m2 / mg / IV / In 100 mL sodium chloride 0.9 % over 20 minutes (via side arm of fast running sodium chloride 0.9 % if peripheral)
*Sodium chloride 0.9 % / 250 / mL / IV
Vincristine 1.4mg/m2 (max 2mg) / mg / IV / In 50 mLsodium chloride 0.9 % free run over 10 minutes
Ondansetron / 8 / mg / PO/IV
  • * Sodium chloride 0.9 % not required for central line administration of daunorubicin
  • Daunorubicin should be infused through a CVAD. Free flow (DO NOT PUMP) if given peripherally
  • #Philadelphia positive patients should not be given Peg-Asparaginase in Induction
  • #Omit day 4 Peg-Asparaginase for Philadelphia negative patients OVER 40 years. These patients should only receive day 18Peg-Asparaginase.
  • Check Antithrombin III and Fibrinogen every 2 days while receiving Peg-Asparaginase
  • Diagnostic LP and IT Methotrexate is given on day 14 (unless there are clinical signs of CNS involvement, in which case the LP is performed earlier)
  • Timing of intrathecal therapy can be moved +/- 3 days to allow administration on specific lists as per local and national guidance

UKALL 14
Induction Phase 1 / Height / cm
Weight / kg
BSA / m2
Day / Date / Time / Agent / Dose / Route / Instructions / Doctor / Nurse / Check / Start / Stop
18 / # Peg-Asparaginase 1000 units/m2
(Philadelphia –ve patients only) / units / IV / In 100mLsodium chloride 0.9 % over at least 1 hour
22 / Ondansetron / 8 / mg / PO/IV / Give one hour prior to chemotherapy
Daunorubicin30mg/m2 / mg / IV / In 100 mL sodium chloride 0.9 % over 20 minutes (via side arm of fast running sodium chloride 0.9 % if peripheral)
*Sodium chloride 0.9 % / 250 / mL / IV
Vincristine 1.4mg/m2 (max 2mg) / mg / IV / In 50 mLsodium chloride 0.9 % free run over 10 minutes
Ondansetron / 8 / mg / PO/IV
23 / Filgrastim / 300 / mcg / subcut / Once daily until count recovery (prescribe on regular medication chart)
  • * Sodium chloride 0.9 % not required for central line administration of daunorubicin
  • Daunorubicin should be infused through a CVAD. Free flow (DO NOT PUMP) if given peripherally
  • # Philadelphia positive patients should not be given Peg-Asparaginase in Induction
  • Check Antithrombin III and Fibrinogen every 2 days while receiving Peg-Asparaginase
  • Commence Induction 2 once platelets are >75 X 109/L and neutrophils > 0.75 X 109/L

Authorised by: Dr P GanlyPharmacists: CInnes / B Harden / August 2012
Review August 2013, April 2016